censavudine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Censavudine (INN) (BMS-986001) is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. It was originally developed at Yale University.   Wikipedia

Chemistry

  • SMILES: CC1=CN([C@@H]2O[C@](CO)(C=C2)C#C)C(=O)NC1=O
  • InChIKey: OSYWBJSVKUFFSU-SKDRFNHKSA-N
  • Mol. Mass: 248.24
  • ALogP: -0.71
  • ChEMBL Molecule:
    censavudine  
More Chemistry

Pharmacology

Alternative names

2',3'-didehydro-3'-deoxy-4'-c-ethynylthymidine | 4'-ed4t | 4'-ethynylstavudine | 4'-ethynyl stavudine | bms-986001 | censavudine

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

HIV Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue